• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ppi_logo_rgb_outlinedv3
address
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact

Communications

COPD Payer research

  1. Home>
  2. category>
  3. Communications>
COPD Payer research

Objectives: Payer research to assess unmet needs in COPD, perceptions of current therapeutic approaches, evidence requirements, attractive value propositions and market access considerations

Therapy Area: COPD (mild/moderate/severe)

Client: USA pharma company

Product/Technology: Drug

Scope: 7 countries (UK, US, Can, Aus, Swe, Fra, Ger)

Our Workplan: Developed multi-country discussion guides and recruited and interviewed senior payers and payer advisors

Project Duration: 14 weeks

Outcome: Key output was a 109 slide presentation detailing our findings per market and drawing cross-market inferences. Analysis included a ranking of importance for many of the aspects investigated (type of data required, design of clinical study, choice of primary endpoint and mechanisms of outcome measurement etc.) as well as a prospective evaluation of how needs and expectations would change over the next few years.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

International Reimbursement planning

  1. Home>
  2. category>
  3. Communications>
International Reimbursement Planning

Objectives: To establish data needs and activities required to achieve reimbursement and market access

Therapy Area: Allergy

Client: Danish pharmaceutical company

Product/Technology: Vaccine

Scope: 11 European countries

Our Workplan: Development of product profile and discussion template followed by fieldwork discussions in each market and analysis of issues

Project Duration: 16 weeks

Outcome: 119 page report and summary presentation provided of our findings and recommendations including health economic requirements, reimbursement issues, necessary clinical data and in-market pre-launch activity plan.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

European P&R planning

  1. Home>
  2. category>
  3. Communications>
case7

Objectives: To advise on such as clinical programme, reimbursement needs, market access, representational and distribution issues for new technology

Therapy Area: Breast cancer

Client: USA device company

Product/Technology: Device incorporating stem cell technology

Scope: UK, Germany, France, Italy, Spain, Netherlands

Our Workplan: Consulted with appropriate in-market stakeholders (clinicians, regulators, payers, pharmacists, logistics) to assess respective issues and provide recommendations

Project Duration: 12 weeks

Outcome: Guidance provided on all pertinent issues including clinical programme design and appropriate QoL instrument for clinical study, DRG (diagnosis related groups) issues and actions, price guidance, specific reimbursement processes and activities and suggested in-market prelaunch activities.

Case Studies

  • Pricing, Early Access Strategy and Launch planning
  • Value and Access Strategy
  • Pricing, Reimbursement and Launch Planning Strategy
  • P&R Due Diligence Assessment for 2 agents
  • COPD Payer research
  • International Reimbursement planning
  • European P&R planning

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

Filed Under: Case Studies

World Orphan Drug Conference, USA

  1. Home>
  2. category>
  3. Communications>
Orphan Drug USA
Adam Barak presenting at the World Orphan Drugs Conference, Washington, USA. April 2016
  • Washington DC, USA -
  • 20 April, 2016.
  • Adam Barak presenting at the World Orphan Drugs Conference, Washington Educational Seminar (full day) Challenges and Solutions for Funding Treatment of Rare Diseases: Payers’ Perspectives.
  • PPi’s Adam Barak and Randy Perry chaired a payer forum where invited payers from the USA (CMS, Aetna and Medicaid) and from France, the UK, Italy Australia and Bulgaria discussed practical guidance for the listing and funding of high-priced drugs used to treat rare conditions
  • PPi also produced a White Paper for this conference (copy available) setting out approaches and examples to obtaining funding for orphan drugs

Conferences

  • Pharma Pricing, Reimbursement & Market Access
  • World Orphan Drug Conference, USA
  • Orphan Drugs and Rare Diseases
  • World Orphan Drug Conference, Europe
  • Cambridge Rare Disease Network, Inaugural Meeting
  • Pharma Pricing and Market Access, Europe
  • ISPOR (International Society for Pharmacoeconomics and Outcomes Research) European Congress
  • Visiongain 9th Annual P&R Conference
  • An Introduction to the Pharmaceutical Industry Today
  • Generics & patent-Expired Pharmaceutical Market
  • European Regulatory Affairs, Health Economics & Pricing Symposium
  • Defending Value and Maximising Profitability of Innovative Pharmaceuticals over their Entire Life Cycles

Filed Under: Conferences

Orphan Drugs and Rare Diseases

  1. Home>
  2. category>
  3. Communications>
PGE
Paradigm
  • London, UK -
  • 15 March, 2016.
  • Adam Barak presenting at the Orphan Drugs and Rare Disease conference. Conference on considerations for securing early advice in Europe.
  • Providing examples and guidance for companies developing medicines for rare diseases. Topics included pricing, access considerations and alternative approaches and needs for securing early payer engagement.

Conferences

  • Pharma Pricing, Reimbursement & Market Access
  • World Orphan Drug Conference, USA
  • Orphan Drugs and Rare Diseases
  • World Orphan Drug Conference, Europe
  • Cambridge Rare Disease Network, Inaugural Meeting
  • Pharma Pricing and Market Access, Europe
  • ISPOR (International Society for Pharmacoeconomics and Outcomes Research) European Congress
  • Visiongain 9th Annual P&R Conference
  • An Introduction to the Pharmaceutical Industry Today
  • Generics & patent-Expired Pharmaceutical Market
  • European Regulatory Affairs, Health Economics & Pricing Symposium
  • Defending Value and Maximising Profitability of Innovative Pharmaceuticals over their Entire Life Cycles

Filed Under: Conferences

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »
PPI Logo

Adding global value through local expertise and insight

Adding global value through local expertise and insight

PPi Healthcare Consulting Ltd
5 The Chambers, Vineyard
Abingdon-on-Thames
Oxfordshire
OX14 3PX, UK

Further information:
E: info@ppi.consulting
T: +44 (0)7811 363098

Privacy Policy

GEP

© copyright 2020
PPi Healthcare Consulting Ltd
All rights reserved

This website uses cookies to improve your experience. To view our privacy policy click here. To change your cookie preferences:Cookie settingsor ACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT